Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug combinations
Pharma
Jazz's almost-withdrawn lung cancer drug shows life
Jazz proposed two phase 3 trials to keep Zepzelca's accelerated approval a few years ago, and one of them has read out positively.
Angus Liu
Oct 15, 2024 10:15am
Exelixis plots FDA prostate cancer filing despite survival miss
Sep 16, 2024 5:00pm
Merck's Keytruda-Lenvima combo triumphs in liver cancer subtype
Sep 14, 2024 10:30am
ESMO: BMS moves Opdualag into phase 3 trials in 1L NSCLC
Sep 14, 2024 2:40am
Gilead unfolds Trodelvy triplet's first-line NSCLC data
Sep 9, 2024 1:45pm
J&J builds case for Tagrisso rival with survival analysis
Sep 8, 2024 2:07pm
